Selection of the optimal scanning agent for thyroid cancer

Thyroid

Volumn 7, Issue 2, 1997, Pages 295-302

  Sisson, James C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; TECHNETIUM 99M;

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MEDULLARY CARCINOMA; PRIORITY JOURNAL; REVIEW; THYROID CANCER; THYROID CARCINOMA;

EID: 0030933369     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1997.7.295     Document Type: Review

References (74)

1. Kusic Z, Becker DV, Saenger EL, Paras P, Gartside P, Wessler T, Spaventi S 1990 Comparison of technetium-99m and iodine-123 imaging of thyroid nodules: Correlation with pathologic findings. J Nucl Med 31:393-399.
2. 131Iin thyroid scanning. Eur J Nucl Med 7:444-446.
3. Berman M, Braverman LE, Burke J, et al. 1988 Report no. 5: I-123, I-124, I-125, I-126, I-130, I-131, and I-132 as sodium iodide. In: MIRD Primer for Absorbed Dose Calculations. The Society of Nuclear Medicine, New York, p. 49-54.
4. Lathrop KA, Atkins HL, Berman M, et al. 1988 Report No. 8: Technetium-99m as sodium pertechnetate. In: MIRD Primer for Absorbed Dose Calculations. The Society of Nuclear Medicine, New York, p. 65-69.
5. Meier C, Braveman L, Ebner S, et al. 1994 Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma. J Clin Endocrinol Metab 78:188-196.
6. Leeper RD, Shimaoka K 1980 Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 9:383-404.
7. Van Nostrand D, Neutze J, Atkins F 1986 Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:1519-1527.
8. Park H, Perkins OW, Edmondson JW, Schnute RB, Manatunga A 1994 Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49-54.
9. Cramp WA, Yatvin MB, Harms-Ringdahl M 1994 Recent developments in the radiobiology of cellular membranes. Acta Oncologica 33:945-952.
10. Thomas SR, Samaratunga RC, Sperling M, Maxon HR III 1993 Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol 20:157-162.
11. 131I in the treatment of thyroid cancer. Thyroid Today 16:1-9.
12. Hoefnagel CA, Delprat CC, Marcuse HR, de Vijlder JJM 1986 Role of thallium-201 total-body scintigraphy in followup of thyroid carcinoma. J Nucl Med 27:1854-1857.
13. Brendel A, Guyot M, Jeandot R, Lefort G, Manciet G 1988 Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 29:1515-1520.
14. Burman KD, Anderson JH, Wartofsky L, Mong DP, Jelinek JJ 1990 Management of patients with thyroid carcinoma: Application of thallium-201 scintigraphy and magnetic resonance imaging. J Nucl Med 31:1958-1964.
15. Charkes ND, Vitti RA, Brooks K 1990 Thallium-201 SPECT increases detectability of thyroid cancer metastases. J Nucl Med 31:147-153.
16. Ramanna L, Waxman A, Braunstein G 1991 Thallium-201 scintigraphy in differentiated thyroid cancer: Comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 32:441-446.
17. Iida Y, Hidaka A, Hatabu H, Kasagi K, Konishi J 1991 Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 32:2098-2100.
18. 201Tl scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Commun 14:365-372.
19. Nakahara H, Noguchi S, Murakami N, Hosi H, Jinnouchi S, Nagamachi S, Ohnishi T, Futami S, Flores LG II, Watanabe K 1996 Technetium-99m-sestamibi scintigraphy compared with thallium-201 in evaluation of thyroid tumors. J Nucl Med 37:901-904.
20. Briele B, Hotze A, Kropp J, et al. 1991 Comparison of 201 Tl and 99m Tc-MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 30:115-124.
21. Balon HR, Fink-Bennett D, Stoffer SS 1992 Technetium-99m-sestamibi uptake by recurrent Hürthle cell carcinoma of the thyroid. J Nucl Med 33:1393-1395.
22. Yen TC, Lin HD, Lee CH, et al. 1994 The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: Comparison with iodine-131 and thallium-201 whole body scans. Eur J Nucl Med 21:980-983.
23. Yen TC, King KL, Yang AH, Liu RS, Yeh SH 1996 Comparative radionuclide imaging of metastatic insular carcinoma of the thyroid: Value of technetium-99m-(V)DMSA. J Nucl Med 37:78-80.
24. Nemec J, Nyvltova O, Blazek T, Bicek P, Racek P, Novak Z, Preiningerova M, Hubackova M, Krizova M, Zimak J, Bilek R 1996 Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 23:69-71.
25. Klain M, Maurea S, Lastoria S, Cuocolo A, Colao A, Salvatore M 1995 Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 36:2248-2251.
26. Baudin E, Schlumberger M, Lubroso J, Travagli JP, Caillou B, Parmentier C1996 Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81:2541-2544.
27. Bassa P, Kim EE, Inoue T, Wong FCL, Korkmaz M, Yang DJ, Wong WH, Hicks KW, Buzdar AU, Podoloff DA 1996 Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938.
28. Gupta NC, Maloof J, Gunel E 1996 Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943-948.
29. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL 1993 Up-take of 18-fluoro-2-deoxy-D-Glucose by thyroid cancer: Implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090-1094.
30. Gagel RF, Robinson MF, Donovan DT, Alford BR 1993 Medullary thyroid carcinoma: Recent progress. J Clin Endocrinol Metab 76:809-814.
31. Marsh DJ, Learoyd DL, Robinson BG 1995 Medullary thyroid carcinoma: Recent advances and management update. Thyroid 5:407-424.
32. Hellman DE, Kartchner M, Van Antwerp JD, Salmon SE, Patton DD, O'Mara R 1979 Radioiodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 48:451-455.
33. Deftos LJ, Stein MF 1980 Radioiodine as an adjunct to the surgical treatment of medullary thyroid carcinoma. J Clin Endocrinol Metab 50:967-968.
34. Nusynowtiz ML, Pollard E, Benedetto AR, Lecklitner ML, Ware RW 1982 Treatment of medullary carcinoma of the thyroid with I-131. J Nucl Med 23:143-146.
35. Jungberg OL, Bondeson L, Bondeson AG 1984 Differentiated thyroid carcinoma, intermediate type: A new tumor entity with features of follicular and parafollicular cell carcinoma. Hum Pathol 15:218-228.
36. Uribe M, Grimes M, Genoglio-Preiser CM, Fein C 1985 Medullary carcinoma of the thyroid gland. Am J Surg Pathol 9:577-594.
37. Elisei R, Pinchera A, Rome C, Gryczynska M, Pohl V, Maenhaut C, Fugazzola L, Pacini F 1994 Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: Evidence of TSH-R gene transcript in medullary histotype. J Clin Endocrinol Metab 78:867-871.
38. Saad MF, Guido JJ, Samaan NA 1983 Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57:124-128.
39. Kwekkeboom DJ, Reubi JC, Lamberts SWJ, Bruining HA, Mulder AH, Oei HY, Krenning EP 1993 In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413-1417.
40. 3]-octreotide; the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731.
41. Krausz Y, Ish-Shalom S, Dejong BJ, Shibley N, Lapidot M, Maaravi Y, Glaser B 1994 Somatostatin-receptor imaging of medullary thyroid carcinoma. Clin Nucl Med 19:416-421.
42. 99Tc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144:339-345.
43. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, Ellison EC, O'Dorisio MS 1995 Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (octreoscan). Sem Nucl Med 25:251-261.
44. Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu A, Ikekubo K, Makimoto K, Iida Y, Konishi J, Morita R, Hata N, Horiuchi K, Yokoyama A, Torizuka K, Kuma K 1984 A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 25:323-325.
45. 99mTc]MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33-38.
46. Baudin E, Lubroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C 1996 Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37:912-916.
47. Bigsby RJ, Lepp EK, Litwin DEM, Wilkinson AA, Matte GG 1992 Technetium 99m pentavalent dimercaptosuccinic acid and thallium 201 in detecting recurrent medullary carcinoma of the thyroid. Canad J Surg 35:388-392.
48. Mojiminiyi OA, Udelsman R, Soper NDW, Shepstone BJ, Dudley NE 1991 Pentavalent Tc-99m DMSA scintigraphy prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid. Clin Nucl Med 16:259-262.
49. Lebouthillier GL, Morais J, Picard M, Picard D, Chartrand R, D'Amour P 1993 Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med 18:657-661.
50. Skowsky RW, Wilf LH 1991 Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid. South Med J 84:636-641.
51. Von Moll L, McEwan AJ, Shapiro B, Sisson JC, Gross MD, Lloyd R, Beals E, Beierwaltes WH, Thompson NW 1987 Iodine-131 MIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl Med 28:979-988.
52. Baulieu JL, Guilloteau D, Delisle MJ, Perdrisot R, Gardet P, Delepine N, Baulieu F, Dupont JL, Talbot JN, Coutris G, Calmettes C 1987 Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. Cancer 60:2189-2194.
53. Yobbagy JJ, Levetter R, Sisson JC, Shulkin BL, Polley T 1988 Scintigraphic portrayal of the syndrome of multiple endocrine neoplasia type-2B. Clin Nucl Med 13:433-437.
54. Tenenbaum F, Lubroso J, Schlumberger M, Mure A, Plouin PF, Caillou B, Parmentier C 1995 Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36:1-6.
55. Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB 1988 New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159-165.
56. O'Driscoll CM, Baker F, Casey MJ, Duffy GJ 1991 Localization of recurrent medullary thyroid carcinoma with technetium-99m-methoxyisobutylnitrile scintigraphy: A case report. J Nucl Med 32:2281-2283.
57. Shih WJ, Stipp V, Magoun S, Ain KB, Pulmano C 1996 Medullary thyroid carcinoma imaged by Tc-99m MIBI SPECT and Tl-201 chloride/Tc-99m pertechnetate subtraction SPECT. Clin Nucl Med 21:213-219.
58. Edington HD, Watson CG, Levine G, Tauxe WN, Yousem SA, Unger M, Kowal CD 1988 Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium-111-labeled monoclonal antibody to CEA. Surgery 104:1004-1010.
59. Manil L, Boudet F, Motte P, Gardet P, Saccavini JC, Lubroso JD, Schlumberger M, Caillou B, Bazin JP, Ricard M, Bellet D, Bohuon C, Tubiana M, Di Paola R, Parmentier C 1989 Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma. Cancer Res 49:5480-5485.
60. 2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 74:157-163.
61. Peltier P, Curtet C, Chatal JF, Le Doussal JM, Daniel G, Aillet G, Gruaz-Guyon A, Barbet J, Delaage M 1993 Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 34:1267-1273.
62. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM 1996 Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 37:905-911.
63. Tisell LE, Hansson G, Jansson S, Salander H 1986 Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60-66.
64. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup D 1990 Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395-401.
65. Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R 1992 Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization. Thyroid 2:113-117.
66. Halnan KE 1975 The non-surgical treatment of thyroid cancer. Br J Surg 62:769-771.
67. Simpson WJK 1975 Radiotherapy in thyroid cancer. Canad Med Assoc J 113:115-118.
68. Steinfeld AD 1977 The role of radiation therapy in medullary carcinoma of the thyroid. Radiology 123:745-746.
69. Sarrazin D, Fontaine F, Rougier P, Gardet P, Schlumberger M, Travagli JP, Bounik H, Parmentier C, Tubiana M 1984 Place de la radiothérapie dans le traitement des cancers médullaires de la thyroïde. Bull Cancer 71:200-208.
70. Samaan NA, Schultz PN, Hickey RC 1988 Medullary thyroid carcinoma: Prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801-805.
71. 131I]metaiodobenzylguanidine therapy in medullary thyroid cancer: Guy's hospital experience. J Nucl Biol Med 35:323-326.
72. 131I]metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: Results in five cases. J Nucl Biol Med 35:327-331.
73. 131I]metaiodobenzylguanidine therapy administered to two patients with medullary carcinoma of the thyroid. J Nucl Biol Med 35:323-323.
74. 131I]metaiodobenzylguanidine therapy in medullary carcinoma. J Nucl Biol Med 35:334-336.